These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 39036877)

  • 21. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
    Rothan HA; Teoh TC
    Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
    Noroozi Tiyoula F; Aryapour H
    PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.
    Citarella A; Dimasi A; Moi D; Passarella D; Scala A; Piperno A; Micale N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses.
    Sharma A; Kaliya K; Maurya SK
    Curr Top Med Chem; 2021; 21(4):307-328. PubMed ID: 33183205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.
    Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T
    Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting novel structural and functional features of coronavirus protease nsp5 (3CL
    Roe MK; Junod NA; Young AR; Beachboard DC; Stobart CC
    J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33507143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2.
    Ferreira JC; Rabeh WM
    Sci Rep; 2020 Dec; 10(1):22200. PubMed ID: 33335206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro.
    Ferreira JC; Fadl S; Ilter M; Pekel H; Rezgui R; Sensoy O; Rabeh WM
    FASEB J; 2021 Aug; 35(8):e21774. PubMed ID: 34324734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
    Vandyck K; Deval J
    Curr Opin Virol; 2021 Aug; 49():36-40. PubMed ID: 34029993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of inhibition effect and interaction mechanism of antiviral drugs on main protease of novel coronavirus: Molecular docking and molecular dynamics studies.
    Gao X; Wang C; Jiang Y; Zhang S; Zhang M; Liu L; Gao S
    J Mol Graph Model; 2024 Dec; 133():108873. PubMed ID: 39326254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity.
    Al Adem K; Ferreira JC; Fadl S; Rabeh WM
    J Biol Chem; 2023 Feb; 299(2):102790. PubMed ID: 36509143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An automated positive selection screen in yeast provides support for boron-containing compounds as inhibitors of SARS-CoV-2 main protease.
    Sigurdardóttir S; Silva SF; Tiukova I; Alalam H; King RD; Grøtli M; Eriksson LA; Sunnerhagen P
    Microbiol Spectr; 2024 Oct; 12(10):e0124924. PubMed ID: 39162260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
    Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
    J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
    Yassine R; Makrem M; Farhat F
    Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
    Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S
    Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of SARS-CoV-2 papain-like protease (PL
    Garnsey MR; Robinson MC; Nguyen LT; Cardin R; Tillotson J; Mashalidis E; Yu A; Aschenbrenner L; Balesano A; Behzadi A; Boras B; Chang JS; Eng H; Ephron A; Foley T; Ford KK; Frick JM; Gibson S; Hao L; Hurst B; Kalgutkar AS; Korczynska M; Lengyel-Zhand Z; Gao L; Meredith HR; Patel NC; Polivkova J; Rai D; Rose CR; Rothan H; Sakata SK; Vargo TR; Qi W; Wu H; Liu Y; Yurgelonis I; Zhang J; Zhu Y; Zhang L; Lee AA
    Sci Adv; 2024 Aug; 10(35):eado4288. PubMed ID: 39213347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
    Scholle MD; O'Kane PT; Dib S; Gurard-Levin ZA
    Antiviral Res; 2022 Apr; 200():105279. PubMed ID: 35278580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.